STATED VERSUS ACTUAL LIPASE ACTIVITY IN PANCREATIC-ENZYME SUPPLEMENTS - IMPLICATIONS FOR CLINICAL USE

被引：12

作者：

OHARE, MMT

MCMASTER, C

DODGE, JA

机构：

[1] Department of Child Health, Queen’s University of Belfast, Institute of Clinical Science, Belfast

来源：

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION | 1995年 / 21卷 / 01期

关键词：

LIPASE ACTIVITY; PANCREATIN; PANCREATIC ENZYME SUPPLEMENTS;

D O I：

10.1097/00005176-199507000-00010

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

We have carried out an independent investigation of the lipase activity of several pancreatin preparations, including high-lipase preparations of pancreatin that have recently become available. Six preparations from three pharmaceutical companies, Cilag, Duphar, and Merck, were analyzed during the recommended shelf life of the preparation and included a standard and a high-lipase preparation from each manufacturer. All preparations studied showed lipase activity in excess of that which was stated on the packets, and in some cases it was more than twofold. This has important implications for patients and prescribers since changes in apparent enzyme requirements may reflect differences in the potency of batches with time. As it is impossible to evaluate capsule requirements with each new batch prescribed, the presence or relief of symptoms of malabsorption will probably continue to be the way in which most patients monitor their enzyme supplementation on a regular basis. We believe that clinicians need to be aware of the extent of possible intrinsic variation between individual prescriptions before attempting to define possible dose/symptom relationships.

引用

页码：59 / 63

页数：5

共 12 条

[1] Lenaerts C., Beraud N., Castaigne J.-P., Pancrease gastrore-sistance: In vitro evaluation of pH-determined dissolution, J Pediatr Gastroenterol Nutr, 7, pp. S18-S21, (1988)
[2] Bowler I.M., Wolfe S.P., Owens H.M., Sheldon T.A., Littlewood J.M., Walters M.P., A double blind lipase for lipase comparison of a high lipase and standard pancreatic enzyme preparation in cystic fibrosis, Arch Dis Child, 68, pp. 227-230, (1993)
[3] Morrison G., Morrison J.M., Redmond A.O.B., Et al., Comparison between a standard pancreatic supplement and a high enzyme preparation in cystic fibrosis, Aliment Pharmacol Ther, 6, pp. 549-555, (1992)
[4] Littlewood J.M., Kelleher J., Walters M.P., Johnson A.W., In vivo and in vitro studies of microsphere pancreatic supplements, J Pediatr Gastroenterol Nutr, 7, pp. S22-S29, (1988)
[5] Atkinson S.N., A comparative study of the enzyme activity, acid resistance and dissolution characteristics of four enteric coated microsphere preparations of pancreatin, Eur J Clin Res, 1, pp. 37-45, (1991)
[6] Blackberg L., Herneil O., The bile-salt-stimulated lipase in human milk, Eur J Biochem, 116, pp. 221-225, (1981)
[7] Borensztjan J., Reddy M.N., Gladstone A.R., A simple method for the separation of triacylglycerols from fatty acids released in lipase assays, J Lipid Res, 29, pp. 1549-1552, (1988)
[8] Robinson P.J., Sly P.D., High dose pancreatic enzymes in cystic fibrosis, Arch Dis Child, 65, pp. 311-312, (1990)
[9] Kelleher J., Laboratory measurement of nutrition in cystic fibrosis, J R Soc Med, 80, pp. 25-29, (1987)
[10] Kraisinger M., Hochhaus G., Stecenko A., Bowser E., Hendeles L., Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in vitro performance of microencapsulated formulations, J Clin Pharmacol, 34, pp. 158-166, (1994)

← 1 2 →